Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.7%. By the end of trading, Valeant Pharmaceuticals International rose $1.92 (2.2%) to $88.00 on average volume. Throughout the day, 1,792,869 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,971,100 shares. The stock ranged in a price between $86.89-$89.25 after having opened the day at $87.21 as compared to the previous trading day's close of $86.08. Other companies within the Drugs industry that increased today were: Onyx Pharmaceuticals ( ONXX), up 51.3%, Bacterin International Holdings ( BONE), up 20.0%, Prima Biomed ( PBMD), up 18.9% and Oxygen Biotherapeutics ( OXBT), up 18.2%.
Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $28.6 billion and is part of the health care sector. Shares are up 44.0% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk.